Drug Development

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Articles

A changing biopharmaceutical industry is going beyond typically outsourced activities and is using CMOs for more challenging processes. Review the top 10 outsourcing trends.

Outsourcing Trends in Biopharmaceutical Manufacturing

Melanie Sena is community editor of Pharmaceutical Technology.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

PharmaCell to Purchase Cell Therapy Production Facility from TiGenix

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

Will CMOs Provide Sufficient Capacity for Growing Biologics Demand?

NCI launches trial to assess the utility of genetic sequencing to improve patient outcomes.

National Cancer Institute Announces Genetic Sequencing Trial

Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.

Novozymes Biopharma's Technology Demonstrates Potential for Monthly Drug Dosing

Products enable testing in accordance with methods described in new USP monograph.

Copley Scientific Launches Two New Products for MDI Testing

Competition seeks to encourage academic research and accelerate drug delivery applications.

Catalent Applied Drug Delivery Institute Partners with AAPS on 3rd Annual Global Academic Competition

Cour Pharmaceutical Development Company, a biopharmaceutical company, has published new data showing that its proprietary nanoparticle therapy could potentially reduce inflammation and promote tissue repair and regeneration in patients who have had a heart attack.

Immune Modifying Nanoparticles Reduce Heart Attack Damage

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

Testosterone-Regulated Genes May Affect Vaccine Immunity

A monkey-vaccine study provides insight into HIV research.

Formulation and Drug Delivery